Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Basic science and translational research

2573 - Copenhagen prospective personalized oncology (CoPPO): Genomic profiling to select patients for phase 1 trials


09 Oct 2016


Basic science and translational research


Ida Tuxen


Annals of Oncology (2016) 27 (6): 545-551. 10.1093/annonc/mdw393


I.V. Tuxen1, C.W. Yde2, M. Mau-Sørensen1, E. Santoni-Rugiu3, U. Lassen1, F.C. Nielsen2

Author affiliations

  • 1 Department Of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 - Copenhagen/DK
  • 2 Department Of Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, 2100 - Copenhagen/DK
  • 3 Dept. Of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen/DK


Abstract 2573


Advanced technologies can be used to portray genomic alterations (GA) that potentially drive tumor growth. We have established a sequencing and array based pipeline to identify GA to select patients (pts) who might benefit from novel targeted treatments and to enrich the population in phase 1 trials with pts that harbor specific targets. A total of 300 pts are referred annually based on 25 ongoing phase 1 trials.


Adults with advanced solid tumors referred to a dedicated Phase 1 Unit were offered biopsy for mapping of GA. Three fresh tumor 18 G needle biopsies were taken, two were stored in RNAlater® (Life Technologies) for RNA expression analyses and DNA gene mutation analyses, while one biopsy was formalin-fixed and paraffin-embedded for histopathological analyses to confirm suitability of the material, including the presence of min. 100 tumor cells. SNP-array from tumor and whole exome sequencing (WES) from DNA (tumor and blood) were performed using sequence capture and Illumina sequencing to call tumor specific mutations. WES from blood was used to subtract germline polymorphisms. Expression levels of therapeutic targets were revealed by expression Array and RNA-seq from tumor RNA. A tumor board reviewed results. Pts with specific GA that could be targeted with drugs in development were enrolled in phase 1 trials. Individualized treatment with marketed drugs (Off-label) or non-approved drugs (Named pt program) were offered according to level of existing evidence.


Between May 2013 and April 2016, we screened 366 heavily pretreated pts with solid tumors. In 297 pts (81%) a biopsy was taken. In 283 (77%) we achieved sufficient tumor tissue to perform a full genomic profile. An actionable target was identified in 215 pts (75%) out of 283 pts. Mean time from biopsy to reporting of results was 36 days. 153 pts with an actionable target were eligible for treatment. 57 pts (20%) were treated according to the findings of either mutations or RNA expression levels of treatment targets in phase 1 trials (N = 39) or Off-label treatment/Named pt program (N = 18).


Establishing sequencing and array-based pipeline for enrichment of patients to phase 1 trials is feasible in a Phase 1 Unit.

Clinical trial identification


Legal entity responsible for the study

Rigshospitalet, Copenhagen


Region H


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings